Regeneron Pharmaceuticals vs Vertex Pharmaceuticals
Regeneron Pharmaceuticals is the larger business, with $14.34bn of revenue in fiscal 2025 against $12.00bn for Vertex Pharmaceuticals (1.2 times as much). Vertex Pharmaceuticals grew faster (8.9% against 1.0%). Vertex Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 32.9% against 31.4%.
| Latest fiscal year | Regeneron PharmaceuticalsREGN, 2025 | Vertex PharmaceuticalsVRTX, 2025 |
|---|---|---|
| Revenue | $14.34bn | $12.00bn |
| Revenue growth | 1.0% | 8.9% |
| Net income | $4.50bn | $3.95bn |
| Operating margin | 24.9% | — |
| Net margin | 31.4% | 32.9% |
| Return on equity | 14.9% | 22.5% |
| Free cash flow | $4.08bn | $3.19bn |
| Cash | $3.12bn | $5.08bn |
| Total debt | $1.99bn | $0 |
| Debt to equity | 6.4% | — |
| Dividend per share | — | — |
| Dividend yield | 0.4% | — |
| Share buybacks | $3.44bn | $2.02bn |
| Employees | 15,410 | 6,400 |
| Market value | $102.62bn | $134.42bn |
| Price vs our value range | Within our value range | Above our value range |
| Moat score | 86 (Strong) | 76 (Strong) |
| Insider trades, 12 months | 0 buys, 105 sales | 0 buys, 93 sales |